CN113862262A - 用于检测丙型肝炎病毒的raa引物、试剂盒及其应用 - Google Patents
用于检测丙型肝炎病毒的raa引物、试剂盒及其应用 Download PDFInfo
- Publication number
- CN113862262A CN113862262A CN202111415246.1A CN202111415246A CN113862262A CN 113862262 A CN113862262 A CN 113862262A CN 202111415246 A CN202111415246 A CN 202111415246A CN 113862262 A CN113862262 A CN 113862262A
- Authority
- CN
- China
- Prior art keywords
- raa
- primer
- detection
- virus
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000711549 Hepacivirus C Species 0.000 title claims abstract description 33
- 238000001514 detection method Methods 0.000 claims abstract description 52
- 230000003321 amplification Effects 0.000 claims abstract description 37
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 37
- 238000000034 method Methods 0.000 claims abstract description 15
- 238000004587 chromatography analysis Methods 0.000 claims abstract description 12
- 238000006243 chemical reaction Methods 0.000 claims description 25
- 238000012360 testing method Methods 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 238000011901 isothermal amplification Methods 0.000 claims description 9
- 239000013612 plasmid Substances 0.000 claims description 9
- 238000011144 upstream manufacturing Methods 0.000 claims description 8
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 7
- 239000007853 buffer solution Substances 0.000 claims description 6
- 239000008367 deionised water Substances 0.000 claims description 6
- 229910021641 deionized water Inorganic materials 0.000 claims description 6
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 claims description 6
- 229940069446 magnesium acetate Drugs 0.000 claims description 6
- 235000011285 magnesium acetate Nutrition 0.000 claims description 6
- 239000011654 magnesium acetate Substances 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 238000002123 RNA extraction Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000013642 negative control Substances 0.000 claims description 4
- 239000013641 positive control Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000003908 quality control method Methods 0.000 claims description 4
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims 2
- 238000005516 engineering process Methods 0.000 abstract description 9
- 230000035945 sensitivity Effects 0.000 abstract description 7
- 238000012216 screening Methods 0.000 abstract description 5
- 230000000007 visual effect Effects 0.000 abstract description 3
- 239000000047 product Substances 0.000 description 11
- 238000013461 design Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 3
- 108020000999 Viral RNA Proteins 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 101150029662 E1 gene Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000013096 assay test Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
- C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
- G01N33/54388—Immunochromatographic test strips based on lateral flow
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/02—Hepadnaviridae, e.g. hepatitis B virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
- G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
- G01N2333/186—Hepatitis C; Hepatitis NANB
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明公开了一种用于检测丙型肝炎病毒的RAA引物、试剂盒及其应用。本发明筛选得到的HCV检测RAA引物特异性好、灵敏度高(最低可检测到10 copies/μL),能够用于制备HCV检测试剂盒及构建RAA扩增体系,并结合侧向流动层析技术实现对HCV快速、低成本的检测及可视化的结果判定,无需复杂的专业背景,使用过程方便快捷,检测结果安全可靠。
Description
技术领域
本发明涉及病毒生物学检测技术领域,具体涉及一种用于检测丙型肝炎病毒的RAA引物、试剂盒及其应用。。
背景技术
丙型肝炎是一种由丙型肝炎病毒( HCV) 引起,经血液传播的疾病,是《中华人民共和国传染病防治法》规定的乙类传染病。科技、卫生健康等部门将丙肝相关研究纳入国家科技计划范畴,强化基础性和应用性研究,支持开展新型预防与治疗技术策略研究,快速检测技术的研发与投入,为全面推进健康中国建设、保护人民群众健康奠定基础。
现阶段对丙肝的常规诊断方法为qPCR、PCR与ELISA,三者虽属于成熟的检测方式,但均需要昂贵设备、检测周期较长(3~4h)、试剂耗材成本高,且目前只能在部分市级疾控中心和三甲医疗机构中开展,检测能力不能满足实际需求,急需一种能在普通实验室操作、无需高档设备、可实现快速检测、直接判读的核酸检测方法。
基于不同原理开发的能够在恒定温度下对DNA 模板进行高效扩增的技术,称为等温扩增技术(isothermal amplification)。近年来,核酸等温扩增技术发展迅速,它摆脱了传统的温度循环仪,可以在短时间内迅速进行扩增反应,其中重组酶聚合酶等温扩增(recombinase polymerase amplification,RPA/RAA)技术显示出了自己多方面的优势,具体体现为:能够在37~42℃恒温条件下,30min内完成对DNA 的扩增,具有反应迅速、操作简单等技术优点,同时还具有高度特异性和敏感性的特点,而且对硬件设备的要求很低,因此被广泛应用于疾病的诊断与防治,特别适合用于体外诊断、兽医、食品安全、生物安全、农业等领域。
而RPA的扩增引物则是整个反应的关键所在,但目前尚无用于引物设计的软件或成熟的设计原则,目前也没有大量的数据为其引物设计提供依据,更没有成熟的经验可供遵循,因而找到适用于丙型肝炎病毒的特异性RPA引物成为当务之急。
公开于该背景技术部分的信息仅仅旨在加深对本发明总体背景技术的理解,而不应当被视为承认或以任何形式暗示该信息构成本领域技术人员所公知的现有技术。
发明内容
本发明的目的在于提供一种用于检测丙型肝炎病毒的RAA引物及试剂盒,以解决现有技术难以快速检测HCV的技术问题;并将其与侧向层析技术相结合,以解决HCV测试成本高、HCV检测结果难以快速直观的呈现的难题。
为解决上述技术问题,本发明采用如下技术方案:
筛选得到一种用于检测丙型肝炎病毒的RAA引物,其核苷酸序列如下:
上游引物:5’- FITC-CTTGGGATATGATGATGAACTGGTCACCTAC-3’(如SEQ ID NO.1所示);
下游引物:5’- Biotin-AAGAGTAGCATCACAATCAGAACCTTAGCC-3’ (如SEQ ID NO.2所示)。
所述RAA引物可应用于制备丙型肝炎病毒检测相关产品中,如,
制备一种HCV检测试剂盒,包括RAA引物,以及RNA提取试剂、RAA扩增反应试剂、侧向流动层析试纸条、阳性对照品、阴性对照品等。
构建一种用于HCV检测的RAA扩增体系,包括:
41.5μL缓冲液、去离子水10μL、所述上游引物和下游引物各2.5μL、待测样品RNA提取物2μL及280mmol/L醋酸镁溶液2.5μL。
所述HCV检测试剂盒的使用方法,包括如下步骤:
(1)提取丙型肝炎病毒的RNA;
(2)制备阳性标准品,获得阳性质粒;
(3)RAA-LFA检测丙型肝炎病毒
具体而言,是以RNA提取试剂提取待测样品的RNA,利用所述RAA引物及对应的RAA扩增反应试剂进行等温扩增反应,获得RAA扩增产物。
所述等温扩增反应为:向装有反应干粉的0.2mL检测单元管中加入41.5μL缓冲液、去离子水10μL、上游引物和下游引物各2.5μL、模板阳性质粒2μL,最后加入280mmol/L醋酸镁溶液2.5μL,将RAA扩增体系充分混匀,置于水浴锅上,30~42℃反应5~30min,反应结束后获得RAA扩增产物。
同时设置阳性(阳性对照采用阳性质粒为模板)对照和阴性对照(阴性对照采用不含丙肝病毒基因组片段的空载体质粒样品)。
进一步的,将所得RAA扩增产物滴加于胶体金标记侧向层析试纸条的样品垫上,待反应3~10分钟后,观察试纸条上检测线和质控线通过检测线和质控线的出现情况对检测结果进行判断。
优选的,可先将所述RAA扩增产物于37℃下温育5min后,再用200μL PBST缓冲液稀释,并将其滴加至胶体金标记侧向层析试纸条样本孔中,室温温育5~10min后观察结果。检测线呈现红色,则为阳性,检测线不显色,则为阴性。
与现有技术相比,本发明的主要有益技术效果在于:
1.本发明综合考虑了靶标区域情况、RPA引物的长度及其形成二级结构的可能性、GC含量、扩增产物的长度限制等诸多因素,筛选得到能用于HCV快速检测的RAA引物,其特异性好、灵敏度高(最低可检测到10 copies/μL)。
2.本发明在RPA/RAA基础上有机结合胶体金侧流层析试纸技术(Lateral FlowAssay,LFA),能够快速实现对HCV检测结果的可视化判定,无需复杂的专业背景。
3.利用本发明试剂盒进行HCV检测主要包括等温扩增与试纸条判读两个步骤构成,扩增部分时间为10分钟,结果判读部分时间为3~5分钟,较传统的RT-PCR方法缩短近3小时,能满足现场快速、高通量筛查的需求,且检测过程方便快捷,检测结果安全可靠。
附图说明
图1为本发明实施例中丙型肝炎病毒检测流程示意图。
图2为本发明实施例中基于RAA-LFA检测方法所示的敏感性实验结果图。
图3为本发明实施例中基于RAA-LFA检测方法所示的特异性实验结果图。
具体实施方式
下面结合附图和实施例来说明本发明的具体实施方式,但以下实施例只是用来详细说明本发明,并不以任何方式限制本发明的范围。
另外,对于本发明中的数值范围,应理解为还具体公开了该范围的上限和下限之间的每个中间值。在任何陈述值或陈述范围内的中间值以及任何其它陈述值或在所述范围内的中间值之间的每个较小的范围也包括在本发明内。这些较小范围的上限和下限可独立地包括或排除在范围内。
除非另有说明,否则本说明书中使用的所有技术和科学术语具有本发明所述领域的常规技术人员通常理解的相同含义。虽然本发明仅描述了优选的方法和材料,但是在本发明的实施或测试中也可以使用与本说明书所述相似或等同的任何方法和材料。本说明书中提到的所有文献通过引用并入,用以公开和描述与所述文献相关的方法和/或材料。在与任何并入的文献冲突时,以本说明书的内容为准。
实施例一:引物设计与条件优化
RAA扩增的关键在于引物的设计,但RAA不同于常规的PCR反应,目前尚无用于引物设计的软件或成熟的设计原则,也没有大量的数据为其引物设计提供依据,更没有成熟的经验可供遵循;基于长期的实践研究,本发明选取NCBI 收录的HCV 1b基因型毒株及其它6个基因型毒株C/E基因进行序列比对,并审慎选取保守区域作为RRA扩增靶标;综合考虑多种因素如: 1.GC 含量(40~60%);2.长度(30~35nt);3.扩增产物大小(100~300bp)等等。根据设计的上游RAA 引物及下游RAA 引物,进行了交叉配对,并对最佳引物配对做了筛选,获得最优引物。具体见表1。
表1.针对丙型肝炎病毒C/E1基因的保守区设计的RPA引物
采用表1中所设计的RAA引物对进行RAA扩增后,通过琼脂糖凝胶电泳和侧向层析技术进行检测筛选得到F2/R2引物对的扩增效果最好,条带特异性好,没有非特异性扩增。而其它的引物对出现非特异性扩增、引物的扩增效率低等问题。因此,选择引物对F2/R2进行后续的RAA反应条件优化、特异性和敏感性试验。
对RAA反应时间和反应温度进行优化,结果发现,反应温度为37℃,作用5min时,RAA扩增效率最高。本发明优化后的RAA反应条件,其整个基因扩增过程只需一个温度,不需要特殊的仪器设备,操作更简单,适用丙型肝炎病毒的现场快速检测。
实施例二:敏感性和特异性试验
选择标准丙型肝炎病毒质粒样品为模板,双蒸水10倍梯度稀释浓度为108copies/μL-1copies/μL 的标准质粒模板,并以双蒸水作为空白对照,按实施例一中所记载优化后的反应条件进行RAA检测。结果为最低检出模板量为10copies/μL (见图2);灵敏度较常规PCR方法高,且本发明的检测方法更为简单简单、快速,尤其适于现场检测,对实验条件的要求更宽松。
分别用传染性五项疾病中的其它四项甲肝、乙肝、艾滋、梅毒阳性样本提取核酸样本为模板,按实施例一中优化后的反应条件进行RAA,通过凝胶电泳和侧向层析技术进行检测。实验结果如图3所示,只有丙型肝炎病毒为阳性,其它的均为阴性,说明本发明的RAA检测体系特异性良好。
实施例三:应用于患者个体筛查的验证试验
取离体的患者外周血2mL,3000rpm 离5min,取200μL上清,加入含有5.6μgCarrier RNA的560μL的AVL裂解液中,按QIAamp Viral RNA Mini Handbook(Qiagen公司,catalog#52904/52906)说明书提取病毒RNA,洗脱体积 50μL。按照RAA试剂盒操作说明进行,向装有反应干粉的0.2mL检测单元管中加入41.5μL缓冲液、去离子水10μL、上游引物和下游引物各2.5μL、模板阳性质粒2μL,最后加入2.5μL 280mmol/L的醋酸镁溶液,将RAA扩增体系充分混匀,置于水浴锅上,30~42℃反应5~30min,反应结束后获得RAA扩增产物。将扩增产物直接滴加于胶体金标记侧向层析试纸条,产生的条带清晰,阳性标本检测线(T线)呈现肉眼可以分辨的红色,阴性标本不显色(T线),控制线(C线)表明检测结果有效。
实施例四:应用于患者批量检测的验证试验
取离体的患者外周血2mL,3000rpm 离5min,取200μL上清。使用全自动核算提取仪批量提取患者血清中的病毒RNA,洗脱体积 50μL。按照RAA试剂盒操作说明进行,向装有反应干粉的0.2mL检测单元管中加入41.5μL缓冲液、去离子水10μL、上游引物和下游引物各2.5μL、模板阳性质粒2μL,最后加入2.5μL 280mmol/L的醋酸镁溶液,将RAA扩增体系充分混匀,置于水浴锅上,30~42℃反应5~30min,反应结束后获得RAA扩增产物。将扩增产物直接滴加于胶体金标记侧向层析试纸条,产生的条带清晰,阳性标本检测线(T线)呈现肉眼可以分辨的红色,阴性标本不显色(T线),控制线(C线)表明检测结果有效。
上面结合附图和实施例对本发明作了详细的说明,但是,所属技术领域的技术人员能够理解,在不脱离本发明构思的前提下,所作的改变、修饰、替代、组合、简化,均应为等效的替代方式,从而形成多个具体的实施例,均为本发明的常见变化范围。
SEQUENCE LISTING
<110> 郑州大学
<120> 用于检测丙型肝炎病毒的RAA引物、试剂盒及其应用
<130> /
<160> 2
<170> PatentIn version 3.2
<210> 1
<211> 31
<212> DNA
<213> 人工设计
<400> 1
cttgggatat gatgatgaac tggtcaccta c 31
<210> 2
<211> 30
<212> DNA
<213> 人工设计
<400> 2
aagagtagca tcacaatcag aaccttagcc 30
Claims (9)
1.一种用于检测丙型肝炎病毒的RAA引物,其特征在于,其核苷酸序列如下:
上游引物:5’- FITC-CTTGGGATATGATGATGAACTGGTCACCTAC-3’
下游引物:5’- Biotin-AAGAGTAGCATCACAATCAGAACCTTAGCC-3’。
2.一种丙型肝炎病毒检测试剂盒,其特征在于,包括权利要求1所述RAA引物。
3.根据权利要求2所述的试剂盒,其特征在于,还包括RNA提取试剂、RAA扩增反应试剂、侧向流动层析试纸条、阳性对照品、阴性对照品。
4.一种用于检测丙型肝炎病毒的RAA扩增体系,其特征在于,包括:
41.5μL缓冲液、去离子水10μL、权利要求1所述上游引物和下游引物各2.5μL、待测样品RNA提取物2μL及280mmol/L醋酸镁溶液2.5μL。
5.权利要求2所述试剂盒的使用方法,其特征在于,包括如下步骤:
以RNA提取试剂提取待测样品的RNA,利用所述RAA引物及对应的RAA扩增反应试剂进行等温扩增反应,获得RAA扩增产物。
6.根据权利要求5所述的使用方法,其特征在于,所述等温扩增反应为:向装有反应干粉的0.2mL检测单元管中加入41.5μL缓冲液、去离子水10μL、上游引物和下游引物各2.5μL、模板阳性质粒2μL,最后加入280mmol/L醋酸镁溶液2.5μL,将RAA扩增体系充分混匀,置于水浴锅上,30~42℃反应5~30min,反应结束后获得RAA扩增产物。
7.根据权利要求5所述的使用方法,其特征在于,还包括如下步骤:将所得RAA扩增产物滴加于胶体金标记侧向层析试纸条的样品垫上,待反应3~10分钟后,观察试纸条上检测线和质控线通过检测线和质控线的出现情况对检测结果进行判断。
8.根据权利要求7所述的使用方法,其特征在于,先将所述RAA扩增产物于37℃下温育5min后,再用200μL PBST缓冲液稀释,并将其滴加至胶体金标记侧向层析试纸条样本孔中,室温温育5~10min后观察结果。
9.权利要求1所述RAA引物在制备丙型肝炎病毒检测相关产品中的应用。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111415246.1A CN113862262B (zh) | 2021-11-25 | 2021-11-25 | 用于检测丙型肝炎病毒的raa引物、试剂盒及其应用 |
PCT/CN2022/126394 WO2023093387A1 (zh) | 2021-11-25 | 2022-10-20 | 用于检测丙型肝炎病毒的raa引物、试剂盒及其应用 |
US18/058,851 US20230295752A1 (en) | 2021-11-25 | 2022-11-25 | Raa primers and kits for detection of hepatitis c virus |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111415246.1A CN113862262B (zh) | 2021-11-25 | 2021-11-25 | 用于检测丙型肝炎病毒的raa引物、试剂盒及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113862262A true CN113862262A (zh) | 2021-12-31 |
CN113862262B CN113862262B (zh) | 2023-10-17 |
Family
ID=78985356
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111415246.1A Active CN113862262B (zh) | 2021-11-25 | 2021-11-25 | 用于检测丙型肝炎病毒的raa引物、试剂盒及其应用 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20230295752A1 (zh) |
CN (1) | CN113862262B (zh) |
WO (1) | WO2023093387A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023093387A1 (zh) * | 2021-11-25 | 2023-06-01 | 郑州大学 | 用于检测丙型肝炎病毒的raa引物、试剂盒及其应用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114381551B (zh) * | 2021-12-21 | 2024-02-02 | 佛山科学技术学院 | 一种用于检测大口黑鲈虹彩病毒的实时荧光raa引物、探针及试剂盒 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110165559A1 (en) * | 2009-09-17 | 2011-07-07 | Lane Michael J | Lateral flow based methods and assays for rapid and inexpensive diagnostic tests |
CN107541571A (zh) * | 2017-10-20 | 2018-01-05 | 中国农业科学院兰州兽医研究所 | Rt‑rpa与侧向流动层析技术相结合的猪嵴病毒快速检测方法及其检测试剂盒 |
CN108841926A (zh) * | 2018-07-13 | 2018-11-20 | 锦州医科大学 | 一种rt-rpa-侧流层析双重检测戊型肝炎病毒和甲型肝炎病毒的引物、探针及试剂盒 |
CN112501357A (zh) * | 2020-12-22 | 2021-03-16 | 许晏铭 | 一种基于rpa-lfd法检测丙肝病毒的rpa引物及其应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7070790B1 (en) * | 1993-06-29 | 2006-07-04 | The United States Of America As Represented By The Department Of Health And Human Services | Nucleotide and deduced amino acid sequences of the envelope 1 and core genes of isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines |
CN113862262B (zh) * | 2021-11-25 | 2023-10-17 | 郑州大学 | 用于检测丙型肝炎病毒的raa引物、试剂盒及其应用 |
-
2021
- 2021-11-25 CN CN202111415246.1A patent/CN113862262B/zh active Active
-
2022
- 2022-10-20 WO PCT/CN2022/126394 patent/WO2023093387A1/zh unknown
- 2022-11-25 US US18/058,851 patent/US20230295752A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110165559A1 (en) * | 2009-09-17 | 2011-07-07 | Lane Michael J | Lateral flow based methods and assays for rapid and inexpensive diagnostic tests |
CN107541571A (zh) * | 2017-10-20 | 2018-01-05 | 中国农业科学院兰州兽医研究所 | Rt‑rpa与侧向流动层析技术相结合的猪嵴病毒快速检测方法及其检测试剂盒 |
CN108841926A (zh) * | 2018-07-13 | 2018-11-20 | 锦州医科大学 | 一种rt-rpa-侧流层析双重检测戊型肝炎病毒和甲型肝炎病毒的引物、探针及试剂盒 |
CN112501357A (zh) * | 2020-12-22 | 2021-03-16 | 许晏铭 | 一种基于rpa-lfd法检测丙肝病毒的rpa引物及其应用 |
Non-Patent Citations (3)
Title |
---|
BASHAN ZHANG ET AL.: ""Rapid and sensitive detection of hepatitis B virus by lateral flow recombinase polymerase amplifiation assay"", 《JOURNAL OF VIROLOGICAL METHODS》, vol. 291, pages 1 - 6 * |
HAILI WANG ET AL.: ""Rapid Visual Detection of Hepatitis C Virus Using Reverse Transcription Recombinase-Aided Amplification–Lateral Flow Dipstick"", 《FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY》, vol. 12, pages 1 - 10 * |
景志刚 等: ""重组酶聚合酶扩增技术研究进展"", 《生物技术通报》, vol. 32, no. 6, pages 47 - 53 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023093387A1 (zh) * | 2021-11-25 | 2023-06-01 | 郑州大学 | 用于检测丙型肝炎病毒的raa引物、试剂盒及其应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2023093387A1 (zh) | 2023-06-01 |
US20230295752A1 (en) | 2023-09-21 |
CN113862262B (zh) | 2023-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106947838B (zh) | 非洲猪瘟病毒非结构基因实时荧光lamp检测引物组、试剂盒及检测方法 | |
WO2023093387A1 (zh) | 用于检测丙型肝炎病毒的raa引物、试剂盒及其应用 | |
CN106957927A (zh) | 非洲猪瘟荧光pcr检测试剂、非洲猪瘟荧光pcr检测试剂盒及其应用 | |
TWI451086B (zh) | 檢測魚類病原之引子組、方法及套組 | |
CN111286559B (zh) | 检测非洲猪瘟病毒的引物、探针及试剂盒 | |
CN107686863A (zh) | 环介导等温扩增技术检测三种泌尿生殖道支原体的方法 | |
CN107488749A (zh) | 一种检测猪圆环病毒3型的lamp引物及检测方法 | |
CN115466800A (zh) | 一种检测猴痘病毒及其亚型的多重荧光定量pcr试剂盒 | |
CN114774565A (zh) | 一种基于RPA-CRISPR-Cas12a体系可视化检测阴道毛滴虫的试剂盒及方法 | |
Postel et al. | Development of a new LAMP assay for the detection of CSFV strains from Cuba: a proof-of-concept study | |
CN115873993A (zh) | 一种检测乙型肝炎病毒9个基因型的试剂盒及其应用 | |
RU2612137C1 (ru) | Способ идентификации подвидов возбудителя туляремии Francisella tularensis subsp. tularensis, Francisella tularensis subsp. mediasiatica и Francisella tularensis subsp. holarctica | |
KR102019804B1 (ko) | 중증 열성 혈소판 감소 증후군 바이러스 검출용 프라이머 세트 및 검출방법 | |
CN109439801A (zh) | 一种蜜蜂以色列急性麻痹病毒实时荧光rt-pcr检测试剂盒及其检测方法 | |
CN110468222B (zh) | 一组中国黑龙江立克次体的专用检测引物 | |
CN109811073B (zh) | 双重pcr早期快速检测无乳链球菌和海豚链球菌的引物及其应用 | |
CN110607398B (zh) | 一种荧光可视化快速检测猪流行性腹泻病毒的rt-lamp试剂盒 | |
CN116814857A (zh) | 猫细小病毒及其试剂盒和荧光重组酶聚合酶扩增的方法 | |
CN114231649A (zh) | 检测torch五种病原体的引物探针组合、试剂盒及其应用 | |
CN106521038A (zh) | 一种高灵敏度的bhv‑2实时荧光定量pcr检测方法及试剂盒 | |
CN110735005A (zh) | Siv和prrsv多重rt-pcr快速检测试剂盒及引物 | |
CN114990261B (zh) | 用于检测呼吸道感染性疾病病原体的多重qPCR检测试剂 | |
JP7360752B2 (ja) | 重症熱性血小板減少症候群ウイルス遺伝子検出用組成物及びこれを用いた重症熱性血小板減少症候群の診断方法 | |
CN109943634A (zh) | 一种her2基因检测试剂盒及其应用 | |
CN113373266B (zh) | 一种用于检测绵羊肺腺瘤病毒的荧光rpa引物、试剂盒和检测方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |